co 4

Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine 可用于改变真核生物寿命。

AZD-CO-Ph-PEG4-Ph-CO-AZD is a bis-β-lactam linker, commonly employed in the synthesis of antibody-siRNA conjugates.

PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) 是一款专为 PAC 设计的PROTAC-linker偶联物,采用了含有BRD4降解剂GNE-987的构造,并通过3个PEG的linker进行连接.该化合物也是一种效率高的点击化学试剂,内含Azide基团,可通过铜催化的叠氮-炔环加成反应(CuAAc)与含Alkyne基团的分子反应.此外,它还能通过与含DBCO或BCN基团的分子进行菌株促进的炔-叠氮环加成反应(SPAAC)进行反应.

Amino-PEG4-(CH2)3CO2H is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Propargyl-PEG4-CH2CO2-NHS is a PEG derivative containing a propargyl group and an NHS group. The hydrophilic PEG spacer increases solubility in aqueous media.

Boc-Aminooxy-PEG4-CH2CO2H is a polyethylene glycol (PEG) derivative serving as a PROTAC linker for the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Cyclooctyne-O-amido-PEG4-VC-PAB-Gly-Gly-NH-O-CO-Exatecan 为一种用于ADC中的drug-linker偶联物，其ADC毒素分子为Exatecan。

Me-(S,R,S)-AHPC-CO-CH2-PEG4-O-CH2-COOH 是一种由 E3 连接酶配体和连接子组成的化合物，适用于合成 PROTAC 降解剂 MS4322。

Ala-CO-amide-C4-Boc 为一种可降解 (cleavable) 的ADC linker，适用于抗体偶联活性分子 (ADC) 的合成。

(S,R,S)-AHPC-CO-C4-bromine 是合成PROTAC时使用的E3连接酶配体-连接子偶联物。此化合物包含E3连接酶配体和连接子两个成分。

PCO 400 是一种 comakalim 类似物，可作为一种选择性强的 ATP 敏感型 K+ 通道开放剂。

PROTAC-O4I2 是一种靶向剪接因子 3B1 (SF3B1) 的 PROTAC连接体， 在 K562 细胞中促使 FLAG-SF3B1 降解，IC50 值为 0.244 μM。PROTAC-O4I2 促使 K562 WT 细胞凋亡 (apoptosis)。

AtPCO4-IN-1是一种高选择性的AtPCO4抑制剂，具有IC50值为264.4μM。

4-Methylmorpholine N-oxide 常用作氧化反应中的共氧化剂和牺牲催化剂。

Co 101244 hydrochloride (4-Piperidinol, 1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-Methylphenyl)Methyl]-,hydrochloride) 是一种含有 NR2B 的 NMDA 受体拮抗剂。

K-Ras G12C-IN-4 是一种 KRAS G12C 共价抑制剂。

(S,R,S)-AHPC-O-CF3-CO-cyclohexane 属于 E3 泛素酶配体+连接子偶联物 (E3 Ligase Ligand-Linker Conjugates) 类型，该化合物在合成 PROTAC SMARCA2 4-degrader-20 中有重要应用。

Paromomycin (Sulfate Salt) is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. Paromomycin in combination with sodium stibogluconate has proven to be effective in African and Indian VL (visceral leishmaniasis) and improves survival in African VL[3]. PS (Paromomycin Sulfate) is effective for elimination of B. coli without hematological side effects[4]. The activity of phosphoglucose isomerase was slightly inhibited by 10(-3) M paromomycin sulfate while those of hexokinase, phosphofructokinase and glucose-6-phosphate dehydrogenase were not inhibited[5]. In addition, with regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-aminohippurate clearance were significantly improved (P less than 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man[6]. Significantly higher frequencies of resistance to paromomycin, kanamycin, neomycin and tobramycin were observed in S. aureus isolates from PS (paromomycin supplemented) birds. Paromomycin supplementation resulted in resistance to aminoglycosides in bacteria of PS turkeys. Co-selection for resistance to other antimicrobial agents was observed in E. coli isolates[7].

CO delivery molecule 1 (compound 4) exhibits subcellular localization in the endoplasmic reticulum, mitochondria, and lysosomes. Such localization leads to the manifestation of CO-induced toxicity effects. Notably, the anti-inflammatory properties of CO delivery molecule 1, quantified through TNF-α suppression, are evident at nanomolar concentrations even without CO release. Furthermore, visible-light-induced CO release further enhances its anti-inflammatory effects [1].

RO7122290 是一种双特异性抗体样融合蛋白，其结构由 T 细胞共刺激免疫受体 4-1BB (CD137) 的三聚体配体与靶向肿瘤相关成纤维细胞活化蛋白 (FAP) 的抗原结合片段 (Fab) 组成，展现出潜在的免疫调节和抗肿瘤活性。它可能用于治疗晚期实体瘤。分子量：177.78 KD。

(S,R,S)-AHPC-O-CF3-CO-cyclohexene-Bpin 属于E3 泛素酶配体+连接子偶联物类化合物。(S,R,S)-AHPC-O-CF3-CO-cyclohexene-Bpin 主要应用于制备PROTAC SMARCA2 4-degrader-20。

(S,R,S)-AHPC-Ala-CO-cyclohexene-Bpin 属于 E3 泛素酶配体+连接子偶联物 (E3 Ligase Ligand-Linker Conjugates) 类型。此化合物主要应用于制备 PROTAC SMARCA2 4-degrader-23。

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).

SFNGGP-NH2是一种具有生物活性的肽。PAR-3是一种与凝血酶高亲和力结合的受体，其mRNA在人类皮肤肥大细胞中得到表达。研究指出，蛋白酶激活受体（PAR）在瘙痒反应中的作用涉及组胺依赖性及独立途径。虽然PAR-3本身不直接诱发瘙痒，却可能与PAR-4共同促发此症状。它们的共同表达可增强凝血酶的效应，这表明PAR-3单独时不进行跨膜信号传导，而是作为激活PAR-4的协同因子。